NASDAQ:KMTS - Nasdaq - BMG524411052 - Common Stock - Currency: USD
22.52
+0.33 (+1.49%)
The current stock price of KMTS is 22.52 USD. In the past month the price decreased by -10.35%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.81 | 231.29B | ||
ISRG | INTUITIVE SURGICAL INC | 72.01 | 197.20B | ||
BSX | BOSTON SCIENTIFIC CORP | 39.32 | 157.07B | ||
SYK | STRYKER CORP | 30.63 | 146.67B | ||
MDT | MEDTRONIC PLC | 14.76 | 104.12B | ||
BDX | BECTON DICKINSON AND CO | 12.39 | 50.02B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.32 | 44.71B | ||
IDXX | IDEXX LABORATORIES INC | 45.31 | 41.86B | ||
RMD | RESMED INC | 27.12 | 36.10B | ||
DXCM | DEXCOM INC | 51.72 | 33.46B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.44 | 32.51B | ||
STE | STERIS PLC | 26.36 | 24.19B |
Kestra Medical Technologies Ltd. operates as a commercial-stage, wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington. The company went IPO on 2025-03-06. The firm has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The firm's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
KESTRA MEDICAL TECHNOLOGIES
3933 Lake Washington Blvd Ne, Suite 200
Kirkland WASHINGTON US
Employees: 0
Phone: 14252798002
The current stock price of KMTS is 22.52 USD. The price increased by 1.49% in the last trading session.
The exchange symbol of KESTRA MEDICAL TECHNOLOGIES is KMTS and it is listed on the Nasdaq exchange.
KMTS stock is listed on the Nasdaq exchange.
12 analysts have analysed KMTS and the average price target is 28.05 USD. This implies a price increase of 24.56% is expected in the next year compared to the current price of 22.52. Check the KESTRA MEDICAL TECHNOLOGIES stock analysts ratings, price target forecast and up-and down grades for more detailed information.
KESTRA MEDICAL TECHNOLOGIES (KMTS) has a market capitalization of 1.16B USD. This makes KMTS a Small Cap stock.
KESTRA MEDICAL TECHNOLOGIES (KMTS) currently has 0 employees.
KESTRA MEDICAL TECHNOLOGIES (KMTS) has a support level at 22.19 and a resistance level at 24.62. Check the full technical report for a detailed analysis of KMTS support and resistance levels.
The Revenue of KESTRA MEDICAL TECHNOLOGIES (KMTS) is expected to grow by 113.57% in the next year. Check the estimates tab for more information on the KMTS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KMTS does not pay a dividend.
KESTRA MEDICAL TECHNOLOGIES (KMTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.04).
The outstanding short interest for KESTRA MEDICAL TECHNOLOGIES (KMTS) is 4.08% of its float. Check the ownership tab for more information on the KMTS short interest.
ChartMill assigns a technical rating of 3 / 10 to KMTS.
ChartMill assigns a fundamental rating of 2 / 10 to KMTS. Both the profitability and financial health of KMTS have multiple concerns.
Over the last trailing twelve months KMTS reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS decreased by -16.26% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -83.03% | ||
ROE | -365.94% | ||
Debt/Equity | 1.57 |
ChartMill assigns a Buy % Consensus number of 85% to KMTS. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 0.96% and a revenue growth 113.57% for KMTS